Prevention And Management Of Chemotherapy-Induced Peripheral Neuropathy In Survivors Of Adult Cancers

Publication Date: July 14, 2020

Key Points

Key Points

  • Chemotherapy-induced neuropathy (CIPN) is a serious clinical problem caused by a substantial number of cytotoxic drugs, including taxanes, platinums, vinca alkaloids, epothilones, eribulin, and bortezomib.
  • No agents are recommended for the prevention of CIPN.
    • Duloxetine is the only agent that has appropriate evidence to support its use, but the amount of benefit from duloxetine is limited.
  • Therefore, prevention and minimizing risk are the primary objectives.
  • Because patients with CIPN can have balance troubles and a higher chance of falling, it is reasonable to consider physical and/or occupational therapy approaches for patients with such CIPN-related disabilities.

Prevention

Prevention

...of chemotherapy-induced peripheral neuropath...

...endation 1.1Clinicians should assess the...

...ion 1.2Clinicians should NOT offer,...

...1.3Outside the context of a clinical tr...

....4Clinicians should NOT offer the f...


Treatment

...atment...

...ment of chemotherapy-induced perip...

...ecommendation 2.1Clinicians should asse...


...of chemotherapy-induced peripheral neurop...

...ecommendation 3.1For cancer patients experiencin...

...ion 3.2Outside the context of a clinical trial, n...


Summary of Recommendations

...mendationsHaving trouble viewing table? Expand...